[Complex therapy of chronic viral hepatitis, occurring in combination with opisthorchosis].
OBJECTIVE
To design and substantiate an effective combined therapy scheme for patients with chronic viral hepatitis (CVH) and chronic opisthorchiasis (CO).


METHODS
10 patients with CHB and 12 patients with CHB + C in the presence of CO. All the patients have undergone clinical and device examinations before the treatment and in the course of therapy with biltricide and reaferon.


RESULTS
Patients with CVH at the stage of moderate activity and in the phase of virus replication received antihelminthic therapy with biltricide which caused neither complications nor deterioration, antihelminthic effect was observed in 20 of 22 patients. In a month, the patients started on reaferon given for therapy of hepatitis. As a result, all the patients improved clinically with normalization of biochemical blood parameters. Markers of viral hepatitides disappeared in 17 of 22 patients.


CONCLUSIONS
Combined therapy of CVH in active process in the presence of CO may include antihelminthic and antiviral treatment and should be staged.
Chuĭkova
K I
KI
D000871:Anthelmintics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009889:Opisthorchiasis / Q000150:complications / Q000188:drug therapy*; D011223:Praziquantel / Q000627:therapeutic use*; D011994:Recombinant Proteins; D014779:Virus Replication
D000871:Anthelmintics; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011223:Praziquantel